Translating Pre-Clinical Research to Clinical Patient Care™

JMSACL Logo
Educational Grant Partners: Why no logos? CME.
Golden West Diagnostics


Brian Kelly

SCIEX


Agenda (Preliminary) - View Program

Wednesday, March 20

Time

Sessions

Registration Desk Open

Location: Serra Foyer (Conference Ctr > Ground Floor)

Industry Breakfast Workshop : Thermo Fisher Scientific

Location: Steinbeck 1 (Conference Ctr > 2nd Floor)

Industry Breakfast Workshop : Indigo BioAutomation

Location: Steinbeck 2 (Conference Ctr > 2nd Floor)

Industry Breakfast Workshop : Waters Corporation

Location: Steinbeck 3 (Conference Ctr > 2nd Floor)

Industry Breakfast Workshop : Open Slot : None Scheduled

Location: Colton (Conference Ctr > 2nd Floor)

Coffee Break

Location: Steinbeck Foyer (Conference Ctr > 2nd Floor)

Plenary : Mass Spectrometry as a Driver for Discovery of Biomarkers and Therapeutic Targets in Lymphoma

Location: Steinbeck Ballroom (Conference Ctr > 2nd Floor)

Kojo Elenitoba-Johnson, MD

Memorial Sloan Kettering Cancer Center

Declaration of Competing Interests

Dr. Elenitoba-Johnson declares no conflicts of interest.

Plenary : Steroid Metabolomics for Diagnostic and Prognostic Biomarker Development

Location: Steinbeck Ballroom (Conference Ctr > 2nd Floor)

Wiebke Arlt, MD DSc FRCP FMedSci

Medical Research Council Laboratory of Medical Sciences

I will discuss steroid metabolomics, the combination of mass spectrometry-based steroid profiling with machine learning-based steroid data analysis. I will provide two clinically relevant examples: (1) the development of a new diagnostic biomarker test for the detection of adrenal cancer, with a timeline covering the last 15 years and including discovery, optimisation and prospective validation - adrenal cancer is rare but regularly discovered upon the investigation of incidentally discovered adrenal nodules, which are detected in 5% of all cross-sectional imaging scans; (2) the exploration of the steroid metabolome in a large comprehensively phenotyped cohort of newly diagnosed and treatment naïve women with polycystic ovary syndrome (PCOS), a condition affecting 10-15% of women worldwide and associated with significantly increased metabolic disease risk. Showing our data from this cohort, I will describe the potential of steroid metabolomics for detailed phenotyping, mechanistic exploration, prognostic prediction and therapeutic stratification in this underserved population.

Declaration of Competing Interests

Dr. Arlt declares no conflicts of interest.

Plenary : Graham Cooks Lifetime Achievement Award & Mini-Lecture : Mass Spectrometry in Diagnostics and Therapeutics: the Long View

Location: Steinbeck Ballroom (Conference Ctr > 2nd Floor)

R. Graham Cooks, PhD

Purdue University

R. Graham Cooks1,2, Nicolás Morato1,2, Andrew Mesecar1,3
1Department of Chemistry, 2Department of Biochemistry, and 3Purdue Institute for Cancer Research, Purdue University. West Lafayette, IN 47907

This talk covers an as-yet-unfinished journey. It describes a suite of methods and instrumentation that is the work of many individuals over a long period. Applications to diagnostics, especially intraoperative diagnostics, are ongoing for brain and other cancers. The long view espoused here, describes a series of steps that stretches from half-century old mass spectrometry to new drug candidates, specifically for the case of prostate cancer.

1. MS and MS/MS: because mass spectrometry (MS) is a well suited to characterizing organic compounds, it can be used to characterize complex mixtures, provided sample ionization produces a corresponding mixture of molecular ions. This 1:1 transformation (molecule -> molecular ion) was first achieved by the then-new method of chemical ionization. This allowed two stages of mass analysis, MS/MS, to became an alternative to GC/MS (and later to LC/MS) for mixture analysis.[1]

2. Ambient ionization: the simplest, most direct form of MS, ionizes objects/materials/samples in the open air. Electrospray ionization provided the lead on atmospheric pressure ionization, but ambient ionization [2] goes further and avoids sample manipulation or purification. Desorption electrospray ionization (DESI) effects ionization by localized solvent extraction.[3]

3. MS imaging: any directed ionizing agent (ions in SIMS, neutrals in FAB, photons in LDI, droplets in DESI) is inherently an imaging method.[4]

4. Biomarker discovery: Comparisons of diseased and healthy tissue point to potential biomarkers, e.g. DESI MS/MS analysis of prostate tissue showed preferential localization of cholesterol sulfate in diseased tissue.[5].

5. Target validation: knockdown studies established an association of cholesterol sulfate transferase with prostate cancer.[6]

6. Late stage functionalization: High throughput DESI instrumentation [7] uses accelerated reactions in microdroplets [8,9] to synthesize large numbers of new drug candidates on the millisecond time scale.[10]

7. Enzyme inhibition: Collection of the functionalized products followed by enzyme kinetic measurements [10] validated inhibition for several particular compounds as potential prostate cancer drugs. 8. Animal, safety and efficacy studies lie in the future.

Support from NCATS and Waters, Inc. is gratefully acknowledged.

[1] R. W. Kondrat and R. G. Cooks, Anal. Chem. 50 (1978) 81A
[2] R. Graham Cooks, Zheng Ouyang, Zoltan Takats, Justin M. Wiseman, Science, 311 (2006) 1566-1570
[3] Zoltán Takáts, Justin Wiseman, Bogdan Gologan and R. Graham Cooks, Science, 306 (2004) 471 – 473
[4] Justin M. Wiseman, Demian R. Ifa, Qingyu Song, R. Graham Cooks”, Angew. Chem. Int. Ed. 45 (2006) 7188 – 7192
[5] Livia S. Eberlin; Allison L. Dill; Anthony B. Costa; Demian R. Ifa; Liang Cheng; Timothy Masterson; Michael Koch; Timothy L. Ratliff; R. Graham Cooks, Anal. Chem., 82 (2010) 3430–3434
[6] Renee E Vickman, Scott A. Crist, Kevin Kerian, Livia Eberlin, R. Graham Cooks, Grant N. Burcham, Kimberly K Buhman, Chang-Deng Hu, Andrew D. Mesecar, Laing Cheng and Timothy Ratliff, Mol. Cancer Res. 14 (2016) 776 – 786
[7] Michael Wleklinski, Bradley P. Loren, Christina R. Ferreira, Zinia Jaman, Larisa Avramova, Tiago J. P. Sobreira, David H. Thompson and R. Graham Cooks, Chem. Sci. 9 (2018) 1647 – 1653
[8] Xin Yan, Ryan M. Bain, and R. Graham Cooks Angew. Chem. Int. Ed. 55 (2016) 12960-12972
[9] R. Graham Cooks, Yunfei Feng, Kai-Hung Huang, Nicolás M. Morato, and Lingqi Qiu, Israel J. Chem. 63 (2023) e202300034
[10] Kai-Hung Huang, Nicolás M. Morato, Yunfei Feng, and R. Graham Cooks Angew. Chem. (2023) e202300956

Declaration of Competing Interests

The Cooks lab receives grant support from Waters.

Exhibits & Lunch Buffet

Location: Exhibit Hall - Serra (Conference Ctr > Ground Floor)

Poster Session 1

Location: Exhibit Hall - Serra (Conference Ctr > Ground Floor)

Scientific Session 1

Location: Steinbeck 1 (Conference Ctr > 2nd Floor)

Scientific Session 1

Location: Steinbeck 2 (Conference Ctr > 2nd Floor)

Scientific Session 1

Location: Steinbeck 3 (Conference Ctr > 2nd Floor)

Scientific Session 1

Location: Colton (Conference Ctr > 2nd Floor)

Scientific Session 1

Location: De Anza 1 (Portola Hotel > Ground Floor)

Poster Session 2 with Poster Tours

Location: Exhibit Hall - Serra (Conference Ctr > Ground Floor)

Sign-up and meet at Tour Rally Point in Booth 8 for Poster Tours.

Scientific Session 2

Location: Steinbeck 1 (Conference Ctr > 2nd Floor)

Scientific Session 2

Location: Steinbeck 2 (Conference Ctr > 2nd Floor)

Scientific Session 2

Location: Steinbeck 3 (Conference Ctr > 2nd Floor)

Scientific Session 2

Location: Colton (Conference Ctr > 2nd Floor)

Scientific Session 2

Location: De Anza 1 (Portola Hotel > Ground Floor)

Exhibits & Happy Hour

Location: Exhibit Hall - Serra (Conference Ctr > Ground Floor)

Take a moment to catch up with vendors and make plans for dinner with colleagues.

Discussion Group : NIH Funding to Support Technology Development, Translation, and Transfer

Location: De Anza 1 (Portola Hotel > Ground Floor)

Kelly Crotty, PhD

National Cancer Institute (NCI)

Technical innovation can improve and transform our ability to understand, prevent, diagnose, and treat human disease. NIH drives early-stage innovative technology development and the translation of emerging tools into laboratory and clinical use through several technology-focused grant programs. Dr. Crotty will discuss several of these programs and the diverse technologies that have been supported through them, as well as resources for tech transfer that are offered through NIH.

Discussion Group : Troubleshooting Cases

Location: De Anza 2 (Portola Hotel > Ground Floor)

Elizabeth Mast

IU Health

Leslie Farris, B.S.

Cleveland Clinic

Kathryn Smith, PhD

ARUP Laboratories

Kayla Moehnke, M.S. in MLS; B.S. in MLS

Mayo Clinic

Emily Chegwidden, MPH

Cleveland Clinic

Rene Garay, B.S. Chemistry

Duke University Health System

An evening of 6 Troubleshooting Case Presentations.

The MSACL Troubleshooting Forum provides a setting for discussion between LC-MSMS users working in clinical diagnostics. The interaction is meant to be collegial, not critical, with the goal of attendees learning from the presenter's experience and the presenter learning from any insight attendees can contribute.

17:45
Positive Bias in Fractionated Vitamin D2-D3 Method as Determined via LC-MS/MS
Elizabeth Mast (IU Health)

18:00
Ordeals of Developing a Method to Measure Low-Level Concentrations of Serum Testosterone and my Troubleshooting Journey
Leslie Farris (Cleveland Clinic)

18:15
Troubleshooting the Transformation of Arsenic Species in Urine by HPLC-ICP-MS
Kathryn Smith (ARUP Laboratories)

18:30
Optimized Extraction Protocol for Analysis of 2,3-Dinor 11β-Prostaglandin F2α in Urine
Kayla Moehnke (Mayo Clinic)

18:45
You Don’t Know What You Don’t Know : How Automating Data Review Helped Uncover Chromatography Variations and Issues
Emily Chegwidden (Cleveland Clinic)

19:00
Failed Proficiency Result for 11-Nor-9-Carboxy-THC
Rene Garay (Duke University Health System)

Career Exploration in Clinical Mass Spectrometry : Networking Event

Location: De Anza 3 (Portola Hotel > Ground Floor)

Laura Sanchez, PhD

University of California, Santa Cruz

Lee Williams

Biotage GB Limited

Kara Lynch, PhD, DABCC

University of California San Francisco

Matthew Crawford

Labcorp

This networking event is geared to early career attendees, but open to all. Get insights through informative, concise presentations on various job profiles within clinical mass spectrometry. Experts and seasoned professionals will guide you through diverse roles, making it easier to envision your own journey in this exciting industry.

More info here

Dinner On Own

Location: Off-site

Recommended Places to Eat

MSACL Hospitality Lounge

Location: Club Room (Portola Hotel > Ground Floor)

Drinks provided.

Discussion Group : FDA Regulation of LDTs

Location: Bonsai (Portola Hotel > Ground Floor)

E. Ellen Jones, PhD

National Center for Toxicological Research, FDA

Regulation of LDTs or laboratory developed tests by the FDA has long been a topic of interest and discussion. With the advent of new technologies and approaches there remains a gap between what is analytically possible with newer instrumentation versus what is currently allowed for regulatory use. Clearly, the FDA is aware of new analytical methods and capabilities and knows that new guidance’s are needed. This workshop will discuss some of the historical information on these LDT’s and provide a perspective from a non-regulatory FDA research scientist who is also working on incorporating novel technologies to inform regulatory decision making within the FDA.